{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T18:23:03Z","timestamp":1749406983070,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T00:00:00Z","timestamp":1566777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T00:00:00Z","timestamp":1566777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12981-019-0236-0","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T12:02:45Z","timestamp":1566820965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Positioning of darunavir\/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)"],"prefix":"10.1186","volume":"16","author":[{"name":"CISAI Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-6358","authenticated-orcid":false,"given":"Lucia","family":"Taramasso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cascio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Menzaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Squillace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Dentone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni F.","family":"Pellican\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Calza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goffredo","family":"Angioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,26]]},"reference":[{"issue":"6","key":"236_CR1","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1128\/JVI.70.6.3378-3384.1996","volume":"70","author":"X Wu","year":"1996","unstructured":"Wu X, Liu H, Xiao H, Conway JA, Kappes JC. Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles. J Virol. 1996;70(6):3378\u201384.","journal-title":"J Virol"},{"key":"236_CR2","first-page":"227","volume":"13","author":"F Tejerina","year":"2011","unstructured":"Tejerina F, Bernaldo de Quir\u00f3s JC. Protease inhibitors as preferred initial regimen for antiretroviral-naive HIV patients. AIDS Rev. 2011;13:227\u201333.","journal-title":"AIDS Rev"},{"key":"236_CR3","unstructured":"EACS Guidelines. 2018. European AIDS Clinical Society. \n                    http:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html\n                    \n                  ."},{"key":"236_CR4","unstructured":"DHHS, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2017. Department of Health and Human Services. \n                    https:\/\/aidsinfo.nih.gov\/contentfiles\/AdultandAdolescentGL003510.pdf\n                    \n                  . Accessed 4 June 2019.\u00a0"},{"issue":"4","key":"236_CR5","first-page":"247","volume":"41","author":"A Antinori","year":"2018","unstructured":"Antinori A, Di Biagio A, Marcotullio S, Sarmati L, Andreoni M, Angarano G, et al. Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol. 2018;41(4):247\u201355.","journal-title":"New Microbiol"},{"key":"236_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1517\/14656566.3.2.81","volume":"3","author":"MR Loutfy","year":"2002","unstructured":"Loutfy MR, Walmsley SL. Salvage antiretroviral therapy in HIV infection. Expert Opin Pharmacother. 2002;3:81\u201390.","journal-title":"Expert Opin Pharmacother"},{"key":"236_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/15284336.2018.1550290","volume":"19","author":"AF Capetti","year":"2018","unstructured":"Capetti AF, De Socio GV, Cossu MV, Sterrantino C, Cenderello G, Cattelan A, et al. Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clin Trials. 2018;19:242\u20138.","journal-title":"HIV Clin Trials"},{"key":"236_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1021\/ml1000257","volume":"1","author":"L Xu","year":"2010","unstructured":"Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, et al. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett. 2010;1:209\u201313.","journal-title":"ACS Med Chem Lett"},{"key":"236_CR9","first-page":"1534","volume":"23","author":"M Markowitz","year":"1993","unstructured":"Markowitz M, Saag M, Powderly W, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1993;23:1534\u20139.","journal-title":"N Engl J Med"},{"issue":"11","key":"236_CR10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1097\/QAD.0000000000001817","volume":"32","author":"JJ Eron","year":"2018","unstructured":"Eron JJ, Orkin C, Gallant J, et al. A week-48 randomized phase-3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2018;32(11):1431\u201342. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000001817\n                    \n                  .","journal-title":"AIDS"},{"key":"236_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1742-6405-11-39","volume":"11","author":"K Tashima","year":"2014","unstructured":"Tashima K, Crofoot G, Tomaka FL, Kakuda TN, Brochot A, Vanveggel S, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014;11:39. \n                    https:\/\/doi.org\/10.1186\/1742-6405-11-39\n                    \n                  .","journal-title":"AIDS Res Ther"},{"key":"236_CR12","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","volume":"5","author":"C Orkin","year":"2018","unstructured":"Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48\u00a0weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5:e23\u201334.","journal-title":"Lancet HIV"},{"issue":"4 Suppl 3","key":"236_CR13","doi-asserted-by":"publisher","first-page":"19824","DOI":"10.7448\/IAS.17.4.19824","volume":"17","author":"M Fisher","year":"2014","unstructured":"Fisher M, McDonald C, Moyle G, Martorell C, Ramgopal M, Laplante F, et al. Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor. J Int AIDS Soc. 2014;17(4 Suppl 3):19824.","journal-title":"J Int AIDS Soc"},{"key":"236_CR14","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/hiv.12530","volume":"18","author":"P Echeverr\u00eda","year":"2017","unstructured":"Echeverr\u00eda P, Bonjoch A, Puig J, Ornella A, Clotet B, Negredo E. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia. HIV Med. 2017;18:782\u20136.","journal-title":"HIV Med"},{"key":"236_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1089\/aid.2018.0178","volume":"35","author":"JR Santos","year":"2019","unstructured":"Santos JR, Curran A, Navarro-Mercad\u00e9 J, Navarro-Mercade J, Ampuero MF, Pelaez P, et al. Simplification of antiretroviral treatment from darunavir\/ritonavir monotherapy to darunavir\/cobicistat monotherapy: effectiveness and safety in routine clinical practice. AIDS Res Hum Retroviruses. 2019;35:513\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"236_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/15284336.2018.1513974","volume":"19","author":"A Mena","year":"2018","unstructured":"Mena A, Cid P, Due\u00f1as C, Garcinu\u00f1o M\u00c1, Lorenzo JF, Margusino L, et al. Darunavir\/cobicistat\u00a0maintains the effectiveness of darunavir\/ritonavir in HIV-infected patients under mono or dual therapy. HIV Clin Trials. 2018;19:197\u2013201.","journal-title":"HIV Clin Trials"},{"key":"236_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"key":"236_CR18","unstructured":"Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 2.0, November 2014 \n                    https:\/\/rsc.tech-res.com\/docs\/default-source\/safety\/daids_ae_grading_table_v2_nov2014.pdf\n                    \n                  .\u00a0Accessed 4\u00a0June 2019.\u00a0"},{"issue":"4","key":"236_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.biopha.2012.12.005","volume":"67","author":"B Menzaghi","year":"2013","unstructured":"Menzaghi B, Ricci E, Carenzi L, Parruti G, Orofino G, Gustavigna M, et al. Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project). Biomed Pharmacother. 2013;67(4):293\u20138.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"236_CR20","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/jac\/dky507","volume":"74","author":"L Calza","year":"2019","unstructured":"Calza L, Colangeli V, Borderi M, Coladonato S, Tazza B, Bon I, et al. Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients. J Antimicrob Chemother. 2019;74(3):731\u20138. \n                    https:\/\/doi.org\/10.1093\/jac\/dky507\n                    \n                  .","journal-title":"J Antimicrob Chemother"},{"key":"236_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12879-018-3268-5","volume":"18","author":"L Taramasso","year":"2018","unstructured":"Taramasso L, Tatarelli P, Ricci E, Madeddu G, Menzaghi B, Squillace N, et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018;18:357.","journal-title":"BMC Infect Dis"},{"key":"236_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/cid\/civ296","volume":"61","author":"JR Santos","year":"2015","unstructured":"Santos JR, Saumoy M, Curran A, Bravo I, Llibre JM, Navarro J, et al. Tenofovir\/emtricitabine inflUence on LIPid metabolism (TULIP) Study Group. The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61:403\u20138.","journal-title":"Clin Infect Dis"},{"key":"236_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/QAI.0b013e3182645648","volume":"61","author":"P German","year":"2012","unstructured":"German P, Liu HC, Szwarcberg J, Hepner M, Andrews J, Kearney BP, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61:32\u201340.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"236_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1086\/524061","volume":"197","author":"M Goicoechea","year":"2008","unstructured":"Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102\u20138.","journal-title":"J Infect Dis"},{"issue":"5","key":"236_CR25","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/j.clinre.2017.03.006","volume":"41","author":"L Taramasso","year":"2017","unstructured":"Taramasso L, Ricci E, Celesia BM, Bonfanti P, Quirino T, Squillace N, et al. Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir\/ledipasvir treatment for HCV infection: much Ado About Nothing? Clin Res Hepatol Gastroenterol. 2017;41(5):e76\u20139.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"236_CR26","unstructured":"Rezolsta Summary of Product characteristics, Jannsen-Cilag ltd, June 2018."},{"key":"236_CR27","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.2147\/DDDT.S147493","volume":"12","author":"N Squillace","year":"2018","unstructured":"Squillace N, Bozzi G, Colella E, Gori A, Bandera A. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. Drug Des Devel Ther. 2018;12:3635\u201343.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"236_CR28","first-page":"10","volume":"2018","author":"G Guaraldi","year":"2018","unstructured":"Guaraldi G, Marcotullio S, Maserati R, Gargiulo M, Milic J, Franconi I, et al. The management of geriatric and frail HIV patients. A 2017 update from the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. J Frailty Aging. 2018;2018(8):10\u20136.","journal-title":"J Frailty Aging"},{"key":"236_CR29","first-page":"235","volume":"12","author":"P Priet","year":"2019","unstructured":"Priet P, Podzamczer D. Switching strategies in the recent era of antiretroviral therapy Expert Rev Clin Pharmacol. 2019;12:235\u201347.","journal-title":"Switching strategies in the recent era of antiretroviral therapy Expert Rev Clin Pharmacol"},{"key":"236_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/QAI.0000000000000849","volume":"71","author":"A Di Biagio","year":"2016","unstructured":"Di Biagio A, Cozzi-Lepri A, Prinapori R, Angarano G, Gori A, Quirino T, et al. Discontinuation of initial antiretroviral therapy in clinical practice: moving toward individualized therapy. J Acquir Immune Defic Syndr. 2016;71:263\u201371.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"236_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1089\/apc.2017.0140","volume":"31","author":"A Di Biagio","year":"2017","unstructured":"Di Biagio A, Lorenzini P, Gustinetti G, Rusconi S, De Luca A, Lapadula G, et al. Durability of second antiretroviral regimens in the Italian Cohort Na\u00efve Antiretrovirals Foundation study and factors associated with discontinuation. AIDS Patient Care STDS. 2017;31:487\u201394.","journal-title":"AIDS Patient Care STDS"},{"key":"236_CR32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2147\/IDR.S152090","volume":"11","author":"P Bagella","year":"2018","unstructured":"Bagella P, De Socio GV, Ricci E, Menzaghi B, Martinelli C, Squillace N, et al. Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project. Infect Drug Resist. 2018;11:615\u201323.","journal-title":"Infect Drug Resist"},{"key":"236_CR33","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/jac\/dky566","volume":"74","author":"A d\u2019Arminio Monforte","year":"2019","unstructured":"d\u2019Arminio Monforte A, Cozzi-Lepri A, Di Biagio A, Marchetti G, Lo Caputo S, Rusconi S, et al. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. J Antimicrob Chemother. 2019;74:1363\u20137 (Epub ahead of print).","journal-title":"J Antimicrob Chemother"},{"key":"236_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/15284336.2018.1440691","volume":"19","author":"A d\u2019Arminio Monforte","year":"2018","unstructured":"d\u2019Arminio Monforte A, Lorenzini P, Cozzi-Lepri A, Mussini C, Castagna A, Baldelli F, et al. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clin Trials. 2018;19:52\u201360.","journal-title":"HIV Clin Trials"},{"key":"236_CR35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/hiv.12628","volume":"19","author":"L Taramasso","year":"2018","unstructured":"Taramasso L, Di Biagio A, Maggiolo F, Tavelli A, Lo Caputo S, Bonora S, et al. First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate\/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate\/emtricitabine: a durability comparison. HIV Med. 2018;19:475\u201384 (Epub ahead of print).","journal-title":"HIV Med"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-019-0236-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12981-019-0236-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-019-0236-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T23:08:05Z","timestamp":1598310485000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-019-0236-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,26]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["236"],"URL":"https:\/\/doi.org\/10.1186\/s12981-019-0236-0","relation":{},"ISSN":["1742-6405"],"issn-type":[{"type":"electronic","value":"1742-6405"}],"subject":[],"published":{"date-parts":[[2019,8,26]]},"assertion":[{"value":"6 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol of the SCOLTA Group was approved by local ethical committees (Comitato Etico Regione Liguria, Ospedale Policlinico San Martino, Italy; Comitato Etico Palermo 1, Italy; Comitato Etico Milano Area 1, Italy; Comitato Etico ASST Valle Olona, c\/o Azienda Ospedaliera \u201cOspedale di Circolo e Fondazione Macchi di Varese\u201d, Italy; Comitato Etico, Universit\u00e0 degli Studi Milano-Bicocca, Monza, Italy; Comitato Etico Interregionale, Policlinico di Bari, Italy; Comitato Etico delle Aziende Sanitarie dell\u2019Umbria (CEAS Umbria), Ellera di Corciano (Perugia), Italy; Comitato Etico dell\u2019Azienda Ospedaliero- Universitaria di Sassari, Italy; Comitato Etico Messina, Italy; Comitato Etico Indipendente di Area Vasta Emilia Centro (CE-AVEC), Bologna, Italy; Comitato Etico Indipendente della A.O.U. di Cagliari, Italy; Comitato Etico Azienda Socio Sanitaria Territoriale ASST Lecco, Italy) and conducted in accordance with the ethical principles stated in the the Declaration of Helsinki. Written consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}